Skip to content
value.today

Gritstone bio, Inc.

Total raised
$100 M
2 rounds on record
Latest round
$45 M
Oct 2022
First round on record
Sep 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Gritstone bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2022$45 MNo. 2$10 to $50 million

Gritstone bio, Inc.: Raise no. 2, Oct 2022

Investors in this round

6 investors had bought by the notice of Nov 8, 2022: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Gritstone bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$45 M of $45 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,399,999
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Allen · Executive Officer, Director
  • Andrew E. Allen · Executive Officer, Director
  • Erin E. Jones · Executive Officer
  • Karin E. Joos · Executive Officer
  • Matthew Hawryluk · Executive Officer
  • Vassiliki Economides · Executive Officer
  • Clare A. Fisher · Director
  • Elaine E. Jones · Director
  • Lawrence E. Corey · Director
  • Naiyer A. Rizvi · Director
  • Shefali E. Agarwal · Director
  • Steve A. Krognes · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Piper Sandler & Co. (CRD 665) · New York, New YorkSold in all US states
  • Evercore Group L.L.C. (CRD 42405) · New York, New YorkSold in all US states

Remarks in the notice

  • On the amounts: “"Includes the sale of (i) 6,637,165 shares of common stock (""Common Stock"") at $2.26 per share and (ii) pre-funded warrants for 13,274,923 shares of Common Stock, at exercise price of $2.26 per share, with $2.2599 per share paid by each warrant purchaser."”

Signed by Vassiliki Economides, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 8, 2022. Read the notice at the SEC.

equity, optionsSEC
Sep 2021$55 MNo. 1$50 to $250 million

Gritstone bio, Inc.: Raise no. 1, Sep 2021

Investors in this round

10 investors had bought by the notice of Oct 22, 2021: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Gritstone bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$55 M of $55 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,233,948
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Allen, M.D., Ph.D. · Executive Officer, Director · President and Chief Executive Officer
  • Celia Economides · Executive Officer · Chief Financial Officer
  • Erin Jones · Executive Officer · Chief Operating Officer
  • James Cho · Executive Officer · Chief Accounting Officer
  • Karin Joos · Executive Officer · Head of Research and Development
  • Matt Hawryluk · Executive Officer · Executive Vice President, Chief Business Officer
  • Rahsaan Thompson, J.D. · Executive Officer · Executive Vice President and General Counsel
  • Elaine Jones, Ph.D. · Director
  • Judith Li · Director
  • Naiyer Rizvi, M.D. · Director
  • Richard Heyman, Ph.D. · Director
  • Shefali Agarwal, M.D., M.P.H. · Director
  • Steve Krognes · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cowen and Company (CRD 7616) · New York, New YorkSold in all US states

Signed by Rahsaan Thompson, J.D., Executive Vice President and General Counsel. Source: SEC Form D, newest notice filed Oct 22, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Gritstone bio, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2022).

    SEC Form D · Nov 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2022

That is all the official record says: Gritstone bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in Gritstone bio, Inc.
InvestorKindAmountRoundRoleSource
Clarus Lifesciences III, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Clarus Ventures III GP, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Clarus Ventures III, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Column Group II GP, LPFund or asset managernot statednot statedHeld Series A and B preferred stock (Form 3, 2018)SEC Form 3
Column Group II, LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Redmile Group, LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Versant Affiliates Fund V, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Versant Ophthalmic Affiliates I, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Versant Venture Capital V (Canada), LPVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Versant Venture Capital V, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 10 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Gritstone bio, Inc.
NameRoleNamed in
Andrew AllenExecutive officerNov 2022
Andrew E. AllenExecutive officerNov 2022
Erin E. JonesExecutive officerNov 2022
Karin E. JoosExecutive officerNov 2022
Matthew HawrylukExecutive officerNov 2022
Vassiliki EconomidesExecutive officerNov 2022
Andrew Allen, M.D., Ph.D.President and Chief Executive OfficerOct 2021
Celia EconomidesChief Financial OfficerOct 2021
Erin JonesChief Operating OfficerOct 2021
James ChoChief Accounting OfficerOct 2021
Karin JoosHead of Research and DevelopmentOct 2021
Matt HawrylukExecutive Vice President, Chief Business OfficerOct 2021
Rahsaan Thompson, J.D.Executive Vice President and General CounselOct 2021
Andrew AllenDirectorNov 2022
Andrew E. AllenDirectorNov 2022
Clare A. FisherDirectorNov 2022
Elaine E. JonesDirectorNov 2022
Lawrence E. CoreyDirectorNov 2022
Naiyer A. RizviDirectorNov 2022
Shefali E. AgarwalDirectorNov 2022
Steve A. KrognesDirectorNov 2022
Andrew Allen, M.D., Ph.D.President and Chief Executive OfficerOct 2021
Elaine Jones, Ph.D.DirectorOct 2021
Judith LiDirectorOct 2021
Naiyer Rizvi, M.D.DirectorOct 2021
Richard Heyman, Ph.D.DirectorOct 2021
Shefali Agarwal, M.D., M.P.H.DirectorOct 2021
Steve KrognesDirectorOct 2021